CliffBio
small molecule

BYVALSON

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

Loss of exclusivityOctober 2027latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameBYVALSON
Active ingredientNEBIVOLOL HYDROCHLORIDE; VALSARTAN
StrengthEQ 5MG BASE;80MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 2016
Marketing statusDISCN

Listed patents

PatentExpiresType
7838552October 2027use U-185
7803838August 2026product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.